Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450-1462 (2019).
Kudo, M. et al. Lenvatinib versus sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma: a phase 3 randomized non-inferiority trial. Lancet 391, 1163-1173 (2018).
Sung, H. et al. World Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209-249 (2021).
Zucman-Rossi, J., Villanueva, A., Nault, J.-C. & Llovet, JM Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149, 1226-1239 (2015).
Llovet, JM et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
Finn, RS et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894-1905 (2020).
Evers, B. et al. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat. Biotechnology. 34, 631-633 (2016).
Zhu, AX et al. RESEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 33, 559-566 (2015).
Matsuki, M. et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 7, 2641–2653 (2018).
Wagle, M.-C. et al. A transcriptional MAPK pathway activity score (MPAS) is a clinically relevant biomarker in several types of cancer. NPJ Precis. Oncol. 2, 7 (2018).
Pirker, R. et al. Expression of EGFR as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer: data analysis from the phase 3 FLEX study. Lancet Oncol. 13, 33-42 (2012).
Kimura, T. et al. The immunomodulatory activity of lenvatinib contributes to the antitumor activity in the hepatocellular carcinoma model Hepa1-6. Cancer Sci. 109, 3993–4002 (2018).
Li, E., Lin, L., Chen, CW & Ou, DL Mouse models for immunotherapy in hepatocellular carcinoma. Cancers (Basel) 11, 1800 (2019).
Keng, VW et al. A transposon-based conditional insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnology. 27, 264-274 (2009).
Him, H. et al. Platelet-derived growth factor requires an epidermal growth factor receptor to activate kinases of the p21-activated kinase family. J. Biol. Chemistry. 276, 26741-26744 (2001).
Lee, S.-W. et al. EGFR-Pak signaling selectively regulates macropinocytosis induced by glutamine deprivation. Dev. Cell 50, 381-392 (2019).
Vaseva, AV et al. The degradation of MYC induced by the suppression of KRAS is thwarted by a compensatory mechanism MEK5-ERK5. Cancer cell 34, 807-822 (2018).
Duncan, JS et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple negative breast cancer. Cell 149, 307-321 (2012).
Lito, P. et al. Relief from profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer cell 22, 668-682 (2012).
Kosoff, RE et al. Pak2 retains endomitosis during megakaryopoiesis and changes the organization of the cytoskeleton. Some blood 125, 2995-3005 (2015).
Kobayashi, S. et al. Transcriptional profiling identifies cyclin D1 as a critical effector downstream of mutant epidermal growth factor receptor signaling. Cancer Res. 66, 11389-11398 (2006).
Philippe, PA et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23, 6657-6663 (2005).
Chan, SL et al. New utility of an old marker: the serial measurement of -foetoprotein to predict the radiological response and survival of patients with hepatocellular carcinoma on systemic chemotherapy. J. Clin. Oncol. 27, 446-452 (2009).
Llovet, JM & Lencioni, R. mRECIST for HCC: performance and new refinements. J. Hepatol. 72, 288-306 (2020).
Ding, X. et al. Genomic and epigenomic characteristics of primary and recurrent hepatocellular carcinomas. Gastroenterology 157, 1630-1645 (2019).
Cremolini, C. et al. Early tumor shrinkage and depth of response predict long-term outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab: results from Gruppo Oncologico’s phase III TRIBE trial del Nord Ovest. Anne. Oncol. 26, 1188-1194 (2015).
Love, MI, Huber, W. & Anders, S. Moderate estimate of fold change and dispersion for RNA-seq data with DESeq2. Biol genome. 15, 550 (2014).
Jin, H. et al. The regulator of isoform 4 of the calcineurin 1 gene, downregulated in hepatocellular carcinoma, prevents proliferation, migration and invasive activity of cancer cells and metastasis of orthotopic tumors by inhibiting nuclear translocation of NFAT1 . Gastroenterology 153, 799-811 (2017).
Mazières, J. et al. Evaluation of EGFR protein expression by immunohistochemistry using the H-score and the magnification rule: re-analysis of the SATURN study. Lung cancer 82, 231-237 (2013).
Sun, C. et al. Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma. Nature 508, 118-122 (2014).
Wang, L. et al. High throughput genetic and functional compound screens identify targets for induction of senescence in cancer. Cell representative. 21, 773-783 (2017).
Schuhmacher, M. et al. The transcriptional program of a human B cell line in response to Myc. Res nucleic acids. 29, 397-406 (2001).
Wang, C. et al. Induce and exploit vulnerabilities for the treatment of liver cancer. Nature 574, 268-272 (2019).
World Medical Association. Helsinki Declaration of the World Medical Association. Ethical Principles for Medical Research Involving Human Subjects. Taurus. World health organ. 79, 373-374 (2001).